Skip to main content
OpenTrials
Completed

NCT Number: NCT00000219

Buprenorphine Dose Alteration Study - 1

The purpose of this study is to examine the effects in buprenorphine dose alterations in opioid dependent individuals being maintained on buprenorphine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–41 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Treatment Research Center

Burlington, Vermont, 05401, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Please contact site for information.

Treatment and study plan

buprenorphine

Drug

Primary outcomes

  1. Opioid withdrawal

  2. Subjective dose estimate

  3. Drug effect characteristics: ARCI

  4. Physiological changes in: pupil diameter

  5. Physiological changes in: blood pressure

  6. Physiological changes in: heart rate

  7. Physiological changes in: respiration

  8. Physiological changes in: skin temperature

Sponsors and collaborators

Lead sponsor

University of Vermont

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Buprenorphine Dose Alteration Study

Important dates

Study start
1991
Study completion
2001
First posted
Sep 21, 1999
Registry last updated
May 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.